FDA Calls for Halt on Marketing of Unapproved Colchicine

Orders companies to stop making, distributing the gout medication
By Monica Smith
HealthDay Reporter

FRIDAY, Oct. 1 (HealthDay News) -- The U.S. Food and Drug Administration has ordered companies manufacturing, distributing, or marketing unapproved single-ingredient oral colchicine to cease doing so.

Colchicine is commonly used to prevent and treat gout and to treat familial Mediterranean fever. Although many single-ingredient oral colchicine products have been used for decades by the medical community, only Colcrys, which includes important safety and drug interaction data with its prescribing information, is approved by the FDA.

Companies are expected to stop manufacturing and shipping colchicine within 45 and 90 days, respectively. Mutual Pharmaceutical/URL Pharma, the manufacturer of Colcrys, has established patient assistance and copay programs to ensure affordable access to colchicine until the FDA approves generic competition for Colcrys.

"The need for drugs to go through the FDA approval process is clearly demonstrated by our review of oral colchicine tablets," Janet Woodcock, M.D., director of FDA's Center for Drug Evaluation and Research, said in a statement. "Without our safety review and proper drug labeling, the old standard of care would likely have continued, to the detriment of patients."

More Information

Copyright © 2010 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events